AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06764368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab + Apatinib
Description: Induction Phase:~Subjects will receive Adebrelimab (1200 mg, Day 1) + Etoposide (100 mg/m2, Days 1-3) + Carboplatin (AUC = 4-5, Day 1) / Cisplatin (75 mg/m2, Day 1) (as determined by the investigator) + Apatinib (250 mg, orally, once daily) in 3-week cycles (Q3W) for 4 to 6 cycles.~Maintenance Phase:~Adebrelimab (1200 mg, Day 1) + Apatinib (250 mg, orally, once daily) will be administered for 1 year or until one of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent by the subject, voluntary withdrawal from the study, or other protocol-specified reasons.
Study NCT06764069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Lead
Description: The Glucotrack Sensor Lead will be inserted into the subclavian vein, using a Seldinger technique, where it will continuously measure blood glucose levels.
Study NCT05501483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg
Description: Starts with 45 mg
Study NCT05501483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Starts with 25 mg
Study NCT05501483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 7 MG
Description: Starts with 3 mg daily for the first 2 weeks
Study NCT06764004 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Product
Description: Human umbilical cord stem cells and exosomes will be used.
Study NCT06764004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleeding and clots
Description: Exosomes obtained from human umbilical cord stem cells will be used
Study NCT06762743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Oral Solution (Test Formulation)
Description: The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
Study NCT06762743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Oral Solution (Reference Formulation)
Description: The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
Study NCT05567744 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Registry
Study NCT05732779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOT intervention
Description: A mobile health application developed by eMocha Health Inc. facilitates asynchronous mobile video directly observed therapy (DOT) intervention, empowering users to track dose-by-dose medication adherence
Study NCT06412185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM383
Description: CM383 Injection
Study NCT06412185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06138106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Product Supplement
Description: Participants will have blood drawn before and one hour after consuming the natural product supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
Study NCT06138106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Participants will have blood drawn before and one hour after consuming the placebo supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
Study NCT06327529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SER 118
Description: Bean High in Phytic Acid and High in Inhibitory Polyphenols
Study NCT06327529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LMP 1001
Description: Bean Low in Phytic Acid and High in Inhibitory Polyphenols
Study NCT06327529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPA 586
Description: Bean Low in Phytic Acid and Low in Inhibitory Polyphenols
Study NCT06327529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KAT B1
Description: Bean High in Phytic Acid and Low in Inhibitory Polyphenols
Study NCT04289376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gaze tracking - no intervention
Description: Monitor gaze as subjects watch a video
Study NCT05214989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Description: Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
Study NCT06325280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise cardiac MRI Assessment
Description: Participants will undergo a standard cardiac MRI to assess resting ventricular structure and function then complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer.
Study NCT06325280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: Cardiopulmonary exercise testing will be performed using a cycle ergometer. Consistent with standard guidelines, workload will progressively increase (10W ramp protocol) such that peak oxygen consumption (VO2peak) is achieved within 8-12 minutes. VO2peak, VO2 at anaerobic threshold, peak power output (PPO), ventilation/carbon dioxide production (VE/VCO2) slope, peak heart rate (HR), and HR recovery at 1- and 3-minutes will be recorded. VO2peak will be converted to age-, weight, and sex-specific norms and a %predicted value.
Study NCT05542810 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Use sports drinks as polyethylene glycol solvents
Description: Using sports drinks as a polyethylene glycol solvent and water as a polyethylene glycol solvent in the control group, the effectiveness of intestinal preparation in the two groups was compared, and the adverse reactions, the acceptability of the solution taste, the timing of oral laxatives, and the willingness to repeat the same intestinal preparation or the willingness to recommend the same intestinal preparation to others were compared.
Study NCT05217095 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Convergence Dialyzer
Description: The Convergence dialyzer with design changes made to FX Coral 600 dialyzer will be tested together with Sidecar. In the dialyzer is integrated centrifugal-flow blood pump.The centrifugal-flow blood pump replaces the peristaltic roller pump of the extracorporeal circuit which pumps blood from patient to the dialyzer and from dialyzer to the patient. The centrifugal-flow blood pump is designed to transport blood from the patient to the dialyzer, and after purification, return the blood to patient.
Study NCT06184711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation+McNeill Dysphagia Therapy Programme
Description: The McNeill Dysphagia Therapy programme (MDTP) combined with Transcranial Magnetic Stimulation (TMS) will be applied to the first experimental group.
Study NCT06184711 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation +McNeill Dysphagia Therapy Programme
Description: The McNeill Dysphagia Therapy programme (MDTP) combined with sham Transcranial Magnetic Stimulation (TMS) will be applied to the sham comparator group.
Study NCT05545319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours
Study NCT06384521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle MIND
Description: Lifestyle MIND is implemented twice a week in the group format, including a physical activities class and a health class. The physical activity class lasts for 60 minutes. Participants engage in physical activities modified from the American College of Sports Medicine guidelines for diabetes. The health class lasts for about 2 hours and is delivered by occupational therapy faculty and students with light refreshments that are friendly for people with diabetes. The first hour of the health class involves psychoeducation and skills training for managing SMI and Type 2 Diabetes Mellitus (T2DM), including topics such as recognizing signs and symptoms of mental disorders and diabetes, goal setting, dealing with setbacks and resistance to change, celebrating culture and holidays, and establishing healthy habits and routines. The second hour of the health class is to address individual needs, social determinants of health, and any needed homework assistance.
Study NCT06384521 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle MIND
Description: Lifestyle MIND is implemented twice a week in the group format, including a physical activities class and a health class. The physical activity class lasts for 60 minutes. Participants engage in physical activities modified from the American College of Sports Medicine guidelines for diabetes. The health class lasts for about 2 hours and is delivered by occupational therapy faculty and students with light refreshments that are friendly for people with diabetes. The first hour of the health class involves psychoeducation and skills training for managing SMI and Type 2 Diabetes Mellitus (T2DM), including topics such as recognizing signs and symptoms of mental disorders and diabetes, goal setting, dealing with setbacks and resistance to change, celebrating culture and holidays, and establishing healthy habits and routines. The second hour of the health class is to address individual needs, social determinants of health, and any needed homework assistance.
Study NCT04879121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO
Study NCT05545319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Participants will receive 1 capsule of ritonavir every 12 hours
Study NCT06184711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Only Transcranial Magnetic Stimulation (TMS) will be applied to the second experimental group.
Study NCT05545319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for nirmatrelvir
Description: Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
Study NCT05918289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended& integrated happy aging active aging program(BIHAAAP)
Description: 12 Weeks intervention devided in to two phases( face to face and home based)
Study NCT05235997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolized Collagen Peptide
Description: Dietary Hydrolized Collagen Peptide sourced from bovine
Study NCT05235997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo look alike the experimental product
Study NCT06489535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RETAIN
Description: There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC).
Study NCT06489535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unrelated videos
Description: These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
Study NCT06363513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aescin in Horse Chestnut
Description: Can aescin reduce bleeding in early hemorrhoid
Study NCT06363513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoid
Description: Can combine aescin and MPFF reduce bleeding in early hemorrhoid
Study NCT06363513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonoid
Description: Can combine aescin and MPFF reduce bleeding in early hemorrhoid
Study NCT04896346 — intervention group
Intervention type: OTHER
Intervention: Punch biopsy
Description: punch biopsies will be used for histologic analysis and biochemical assays
Study NCT04896346 — intervention group
Intervention type: OTHER
Intervention: non-invasive photography, assessments, and measurements
Description: photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
Study NCT06140758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study NCT06140758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study NCT06140758 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Toms of Maine 0 ppm Fluoride Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study NCT06140758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study NCT06140758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study NCT06140758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1100 ppm (0.454% Stannous fluoride) Dentifrice
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Study NCT05534919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefecon
Description: Nefecon is taken orally as capsules once daily for 9 months.
Study NCT06320717 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients
Study NCT04719052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and behavioural intervention
Description: Intervention will receive a specific diet designed following the characteristics of Mediterranean Diet
Study NCT05626114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OpRegen
Description: OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
Study NCT04719052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and behavioural intervention
Description: Control group will receive a specific diet designed following the characteristics of Low fat Diet.
Study NCT06332547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Transfusion Strategy
Description: Blood transfusion at HCT less than 21% or Hb less than 6.0g/dL during CPB, at HCT less than 21% or Hb less than 7.0g/dL in ICU or general ward after surgery
Study NCT04930692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT lymphography with the periareolar injection of iopamidol
Description: Patients who meet the inclusion/exclusion criteria will undergo the CT lymphography with periaoreolar injection of a mixture of 4 mL iopamidol and 2 mL of 1% lidocaine hydrochloride. Computed tomographic images will be obtained 1, 3, 5, and 10 minutes after administration of the iopamidol. Following enhancement of the lymphatic duct, the first lymph node to show enhancement will be defined as the SLN.~No later than 10 days after the CT lymphography patients will receive surgical treatment. During breast cancer surgery identification of the SLN using the ICG-fluorescence method with injection of 2 ml indocyanine green into the skin of the areola and the biopsy of identified SLN will be performed. The comparison of the results of CT lymphography and SLN biopsy will be administrated by the investigator.
Study NCT06332547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Transfusion Strategy
Description: Blood transfusion at HCT less than 24% or Hb less than 8.0g/dL during CPB, at HCT less than 30% or Hb less than 10.0g/dL in ICU or general ward after surgery
Study NCT06411730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986368
Description: Specified dose on specified days
Study NCT04894526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating Energy Intake
Description: To alternate between caloric overconsumption (130% of usual total energy needs) and caloric underconsumption (70% of usual total energy needs) on a daily basis for 6 days/week followed by one ad libitum day for 4 weeks.
Study NCT04894526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Energy Intake
Description: To consume the usual energy intake (100% of total energy needs) on a daily basis for 6 days/week, also followed by one ad libitum day for 4 weeks.
Study NCT06364358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized CKD Education
Description: The intervention is a culturally tailored computer-based adaptive program (developed during this intervention) to educate patients about kidney disease and renal replacement therapy options.
Study NCT06364358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Hospital Care
Description: Computer based patient education materials about general healthy lifestyle that will include information about the importance of a healthy diet, physical activity and medical adherence
Study NCT06194799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-204
Description: ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
Study NCT04887792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
Study NCT05393947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient education
Description: It is planned to provide education to patients about the side effects of chemotherapy.
Study NCT06481800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR)
Description: patients receive progressive muscle relaxation (PMR) for 20 minutes after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
Study NCT04887792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical gelatin capsules will be prepared by filling with inert excipients.
Study NCT05134766 — intervention group
Intervention type: OTHER
Intervention: Observation only
Description: Based on type of SOC applied and the type of CAM products by subject's own decison
Study NCT04696913 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure: Positive COVID-19 infection
Description: Exposure: Positive COVID-19 infection as determined by RT-PCR
Study NCT04696913 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure: Negative COVID-19 infection
Description: Exposure: Negative COVID-19 infection as determined by RT-PCR
Study NCT06489899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEGISUS
Description: PEGISUS is an 8-session intervention for substance use and gender equitable beliefs.
Study NCT05399225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelets to lymphocytes ratio and procalcitonin
Description: Platelets to lymphocytes ratio and procalcitonin in sepsis
Study NCT04947163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Participants will perform home-based IMT twice daily \[once in the morning (between 7:00 and 12:00 am) and once in the evening (between 16:00 and 21:00 pm)\], for 8 consecutive weeks, using a mechanical pressure threshold loading device. In addition, participants in this group will try to increase the inspiratory resistance when the participants feel that 30 breaths are achievable with ease or if the participants could reach 35 consecutive breaths.
Study NCT04947163 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IMT
Description: Participants will perform 60 slow breaths once daily at a load setting of 0 (corresponding to \~15% \[baseline\] MIP), using the same device as the IMT group. For the sham group, the ability to adjust the training load will be prevented using sticky tape applied to the device's load adjuster.
Study NCT03454750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA
Description: 177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks